Innovative Strategy for Targeted Delivery of Precision Medicine Drugs (INSPIRE)
| Diarienummer | |
| Koordinator | Uppsala Therapeutics AB |
| Bidrag från Vinnova | 1 918 560 kronor |
| Projektets löptid | maj 2021 - april 2023 |
| Status | Avslutat |
Viktiga resultat som projektet gav
The aim of the project was to synthesize chemically modified oligonucleotides that are sensitive to stimuli like alkaline phosphatase and esterase. We have developed esterase-sensitive drug-siRNA conjugates and alkaline-sensitive chemically modified siRNA and DisiRNA.
Långsiktiga effekter som förväntas
All our siRNAs are functional in invitro condition tested and the results will be published in due course.
Upplägg och genomförande
As designed several chemically modified oligonucleotides which are responsive to stimuli responsive were synthesized and successfully decortaed with drug nanoparticles.A systematic characterization and their funtional properties has been studied.